Spero Therapeutics (SPRO) Receivables - Other (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Receivables - Other data on file, last reported at $44000.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 93.41% year-over-year to $44000.0; the trailing twelve-month figure through Mar 2026 stood at $44000.0 (down 93.41% YoY), and the FY2025 full-year result was $28000.0, down 99.09% from the prior year.
• Receivables - Other for Q1 2026 stood at $44000.0, up from $28000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $5.0 million in Q1 2024 and bottomed at $28000.0 in Q4 2025.
• The 5-year median for Receivables - Other is $1.6 million (2022), against an average of $2.0 million.
• The widest annual swing landed in 2023, when Receivables - Other soared 227.02%; it then tumbled 99.09% in 2025.
• A 5-year view of Receivables - Other shows it stood at $1.1 million in 2022, then jumped by 42.53% to $1.5 million in 2023, then surged by 99.68% to $3.1 million in 2024, then sank by 99.09% to $28000.0 in 2025, then surged by 57.14% to $44000.0 in 2026.
• The last three Receivables - Other figures came in at $44000.0 (Q1 2026), $28000.0 (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.

Peer Comparison